Canine Mitral Valve Disease
Understand canine mitral valve disease through veterinary science — physiology, breed risk, ACVIM staging, treatment protocols, and what owners need to
What Is Canine Mitral Valve Disease?
Canine mitral valve disease (MMVD), also called myxomatous mitral valve degeneration, is a progressive condition where the mitral valve — the one-way gate between the left atrium and left ventricle — thickens, becomes nodular, and fails to close properly. Blood leaks backward (regurgitates) into the left atrium with each heartbeat. It is the most common acquired heart disease in dogs, affecting roughly 85% of dogs over 13 years old, and is the leading cause of congestive heart failure (CHF) in the species. There is no cure, but staged medical management can extend quality life by months to years.
The Physiology: How a Healthy Mitral Valve Works — and Fails
The canine heart has four chambers. Oxygenated blood returns from the lungs to the left atrium, passes through the mitral valve (a bicuspid valve with two leaflets anchored by chordae tendineae to papillary muscles), and enters the left ventricle. When the ventricle contracts (systole), the mitral valve should snap shut so blood is ejected forward through the aorta to the body.
In MMVD, the valve leaflets undergo myxomatous degeneration — the structural collagen and elastin matrix breaks down and is replaced by glycosaminoglycan-rich myxomatous tissue. The leaflets become thickened, rolled, and nodular. The chordae tendineae may elongate or rupture. The result: the valve cannot seal, and blood regurgitates into the left atrium during systole.
Over time, the left atrium dilates to accommodate the extra volume. The left ventricle undergoes eccentric hypertrophy (dilates and thickens) to maintain forward cardiac output. Initially, these are compensatory mechanisms — the dog shows no symptoms. Eventually, the left atrial pressure rises, pulmonary veins engorge, and fluid leaks into the lung tissue: congestive heart failure.
Key Hemodynamic Cascade
- Valve degeneration → leaflets fail to coapt (close fully)
- Mitral regurgitation (MR) → backward blood flow into left atrium
- Left atrial dilation → increased atrial pressure
- Pulmonary venous hypertension → fluid transudation into alveoli
- Left-sided CHF → coughing, dyspnea, exercise intolerance
- In advanced cases: pulmonary hypertension → right-sided heart failure → ascites, hepatomegaly
Evolutionary Context: Why Small Breeds Are Disproportionately Affected
Ancestral perspective: Wolves and wild canids rarely live past 8-10 years and typically weigh 60-120 lb. Mitral valve degeneration is overwhelmingly a disease of aging small-breed dogs — a population that did not exist in ancestral canids. The intense selective breeding for small body size over the past 200 years created anatomical and physiological mismatches.
Small breeds have proportionally smaller hearts with thinner valve leaflets relative to hemodynamic stress. The same myxomatous degenerative process that might take 15+ years to manifest in a large dog accelerates in a 10-lb Cavalier King Charles Spaniel, sometimes appearing as early as 4-5 years old. This is not an evolutionary "design" — it is an unintended consequence of artificial selection for diminutive size and specific skull conformations that co-segregate with cardiac connective tissue variants.
Breed Predisposition: Which Dogs Face the Highest Risk
| Breed | Typical Onset Age | Estimated Prevalence | Notes |
|---|---|---|---|
| Cavalier King Charles Spaniel | 4-6 years | ~50% by age 5; >90% by age 10 | Most studied breed; polygenic inheritance identified |
| Dachshund (miniature) | 7-9 years | ~30-40% by age 10 | Chondrodysplastic breeds show earlier onset |
| Miniature/Toy Poodle | 8-10 years | ~25-35% by age 12 | Often concurrent with tracheal collapse |
| Chihuahua | 8-11 years | ~20-30% by age 12 | Small heart size complicates echocardiography |
| Cocker Spaniel | 7-10 years | ~20-30% by age 12 | Also predisposed to dilated cardiomyopathy |
| Maltese | 8-10 years | ~25% by age 12 | Patent ductus arteriosus also common |
| Shih Tzu | 9-11 years | ~20% by age 13 | Brachycephalic conformation adds respiratory complexity |
Large-breed dogs (Great Danes, Dobermans, Irish Wolfhounds) are far more likely to develop dilated cardiomyopathy (DCM) rather than MMVD. If your large-breed dog has a heart murmur, DCM should be the primary differential.
ACVIM Staging: How Veterinarians Classify Disease Progression
The American College of Veterinary Internal Medicine (ACVIM) published consensus guidelines (updated 2019) that classify MMVD into four stages. Understanding these stages is critical for owners, because treatment recommendations differ at each stage.
| Stage | Description | Diagnostic Findings | Treatment | Median Survival |
|---|---|---|---|---|
| A | At risk; no structural disease yet | No murmur; normal echo; breed predisposition | Annual screening (echo recommended for Cavaliers starting age 2-3) | Normal lifespan expected |
| B1 | Murmur present; mild valve changes; no heart enlargement | Murmur grade I-III/VI; echo shows valve thickening but normal chamber sizes | No medication; recheck every 6-12 months | Years to progression (many never progress) |
| B2 | Murmur + cardiac enlargement; no CHF signs yet | Murmur ≥III/VI; echo shows left atrial and/or ventricular enlargement; VHS on radiograph ≥10.5 | Pimobendan (0.25-0.3 mg/kg PO q12h) — started here per EPIC study | ~15-24 months to CHF onset (delayed by pimobendan) |
| C | Current or past CHF episodes | Pulmonary edema on radiograph; clinical signs (cough, dyspnea) | Quadruple therapy: furosemide + pimobendan + ACE inhibitor (enalapril/benazepril) + spironolactone | ~6-12 months median (varies widely) |
| D | Refractory CHF; standard therapy failing | Persistent edema despite max doses; may need hospitalization | Escalated diuretics, add sildenafil if pulmonary hypertension, torsemide substitution, palliative care | Weeks to a few months |
The EPIC Study: Why Pimobendan Changed Everything
The EPIC (Evaluation of Pimobendan in dogs with Cardiomegaly) study, published in the Journal of Veterinary Internal Medicine (2016), was a landmark randomized, blinded, placebo-controlled trial involving 76 dogs in Stage B2 MMVD. Key findings:
- Dogs receiving pimobendan had a median time to CHF onset or cardiac death of 44 months, versus 28 months for placebo — a 15-month delay.
- Pimobendan is a positive inotrope (increases heart contractility) and a vasodilator (reduces afterload), reducing regurgitant volume without increasing myocardial oxygen demand.
- The study established the EPIC criteria for starting pimobendan: murmur ≥III/VI, heart rate ≥120 bpm, left atrial enlargement (LA:Ao ≥1.6), and left ventricular internal diameter in diastole (LVIDdN) ≥1.7 on echo.
For owners, this means: if your dog is diagnosed at Stage B2, starting pimobendan before symptoms appear can buy significant symptom-free time. The drug (brand name Vetmedin; generic available) costs approximately $30-$60/month for a 20-lb dog at standard dosing.
Recognizing Symptoms: What Owners Actually Observe
| Symptom | Typical Stage | What's Happening Physiologically | Owner Action |
|---|---|---|---|
| Heart murmur detected at wellness exam | B1-B2 | Turbulent blood flow through regurgitant valve | Request echocardiogram referral |
| Occasional dry cough, especially at night or when excited | B2-C | Enlarged left atrium compressing mainstem bronchi; early pulmonary congestion | Schedule vet visit within 1-2 weeks |
| Exercise intolerance — tires on walks that were previously easy | B2-C | Reduced forward cardiac output; muscles receiving less oxygenated blood | Reduce exercise intensity; vet evaluation |
| Rapid breathing at rest (>30 breaths/minute) | C | Pulmonary edema impairing gas exchange | Urgent vet visit — count breaths for 15 seconds, multiply by 4 |
| Syncope (fainting episodes) | C-D | Transient cerebral hypoperfusion from arrhythmias or low output | Emergency evaluation |
| Abdominal distension (ascites) | D (right-sided failure) | Right heart failure causing systemic venous congestion | Emergency evaluation |
| Anorexia, weight loss (cardiac cachexia) | C-D | Cytokine-mediated muscle wasting; gut edema reducing appetite | Discuss nutritional support with vet |
Resting Respiratory Rate: Your At-Home Monitoring Tool
Count your dog's breaths per minute while they are sleeping or resting quietly. One breath = one chest rise + fall. Normal is 15-25 breaths/minute. If the sleeping respiratory rate consistently exceeds 30 breaths/minute, this is an early indicator of pulmonary edema and warrants prompt veterinary evaluation. Many cardiologists ask owners of Stage B2-C dogs to log this number 2-3 times per week.
Common Misconceptions About Canine Mitral Valve Disease
| Myth | Fact |
|---|---|
| "Coughing means my dog has kennel cough or allergies." | A persistent dry cough in a small-breed senior dog is a hallmark of left atrial enlargement compressing the airways. Always rule out cardiac causes first. |
| "My dog has a heart murmur — that means heart failure." | A murmur indicates turbulent blood flow, not necessarily failure. Many dogs live years in Stage B1-B2 without ever developing CHF, especially with appropriate monitoring and timely pimobendan. |
| "Grain-free diets cause mitral valve disease." | The FDA's investigation into diet-associated DCM focused on dilated cardiomyopathy in large breeds, not MMVD. MMVD is a structural valve degeneration with genetic and age-related etiology, not a nutritional disease. |
| "Supplements like taurine or CoQ10 will reverse valve degeneration." | No peer-reviewed evidence demonstrates that any supplement reverses myxomatous valve changes. Taurine deficiency is linked to DCM in specific breeds (e.g., Golden Retrievers), not MMVD. Do not substitute supplements for prescribed cardiac medications. |
| "Surgery can fix my dog's mitral valve." | Open-heart mitral valve repair has been performed in dogs at a few specialized centers (notably in Japan and France), but it requires cardiopulmonary bypass, costs $20,000-$40,000+, carries significant perioperative mortality, and is not widely available. Medical management remains the standard of care in the US. |
| "My dog is on heart medication, so I can stop vet visits." | Stage C dogs require rechecks every 2-4 weeks initially (to titrate diuretics and monitor kidney function), then every 3 months. Bloodwork (BUN, creatinine, electrolytes) is essential to catch diuretic-induced dehydration or ACE-inhibitor-related azotemia. |
Diagnostic Workup: What to Expect at the Veterinary Cardiologist
If your primary veterinarian detects a murmur and suspects MMVD, a referral to a board-certified veterinary cardiologist (DACVIM-Cardiology) is ideal. Expect the following:
- Echocardiogram (echo): The gold standard. Measures valve morphology, regurgitant jet size, left atrial-to-aortic ratio (LA:Ao), LVIDdN, and estimates pulmonary artery pressure. Cost: $400-$700 at a specialty center.
- Thoracic radiographs (X-rays): Assesses cardiac silhouette size (vertebral heart score, VHS) and detects pulmonary edema or pleural effusion. Cost: $150-$300.
- Electrocardiogram (ECG): Screens for arrhythmias (atrial fibrillation, ventricular premature complexes). Cost: $75-$150.
- Blood pressure measurement: Systemic hypertension can worsen regurgitation. Cost: $30-$50.
- Bloodwork (CBC, chemistry, NT-proBNP): Baseline renal function before starting cardiac medications; NT-proBNP (cardiac biomarker) helps differentiate cardiac from respiratory causes of coughing. Cost: $100-$250.
Total initial cardiology workup typically ranges from $750 to $1,450 at a US specialty center (2025-2026 pricing). Pet insurance with illness coverage can offset 70-90% of these costs if the policy was purchased before diagnosis (pre-existing condition exclusions apply).
Daily Life With a Dog in Stages B2 Through C: Practical Guidance
Medication Management
Stage C dogs typically take 3-5 medications daily. Adherence is non-negotiable — missing even one or two doses of furosemide can precipitate acute pulmonary edema. Use a pill organizer, set phone alarms, and keep a medication log. Ask your vet about compounded flavored suspensions if your dog resists pill-taking.
Exercise Modifications
Stage B2-C dogs benefit from shorter, more frequent walks rather than one long outing. A 20-lb dog with Stage C MMVD might do three 10-minute leash walks per day instead of a single 30-minute walk. Avoid exercising in heat or humidity, which increases cardiac demand. Swimming is generally contraindicated once CHF develops due to the horizontal body position increasing venous return.
Dietary Considerations
Cardiac cachexia affects up to 50% of dogs in Stage C-D. Strategies include:
- Sodium restriction: Moderate (not severe) sodium restriction is recommended once CHF develops. Prescription cardiac diets (e.g., Royal Canin Veterinary Diet Cardiac, Hill's h/d) provide controlled sodium with added omega-3 fatty acids, taurine, and L-carnitine.
- Caloric density: If your dog is losing weight, increase caloric density rather than volume — small, frequent meals of energy-dense food.
- Omega-3 supplementation: EPA/DHA at 30-40 mg/kg combined EPA+DHA per day has anti-inflammatory and anti-cachectic effects. Use a veterinary-specific fish oil product with verified concentrations.
Monitoring and Emergency Preparedness
Keep a "heart diary" recording: resting respiratory rate (3x/week), body weight (weekly), exercise tolerance notes, and any coughing/syncope episodes. Share this log at each recheck. Know the location and hours of your nearest 24-hour emergency veterinary hospital — acute CHF episodes often occur at night.
When to Seek Emergency Care
Go to an emergency veterinary hospital immediately if your dog exhibits:
- Respiratory rate >40 breaths/minute at rest, or labored/open-mouth breathing
- Blue or gray mucous membranes (gums, tongue)
- Repeated syncope (fainting) episodes
- Sudden inability to lie down comfortably (orthopnea — sitting/standing to breathe)
- Coughing up pink, frothy fluid (pulmonary edema)
Always consult your veterinarian for any changes in your dog's condition. This article provides educational information and does not replace professional veterinary diagnosis or treatment.
Frequently Asked Questions
How long can a dog live with canine mitral valve disease?
Survival varies enormously by stage at diagnosis. Dogs diagnosed at Stage B1 may never develop CHF and can live a normal lifespan. Stage B2 dogs started on pimobendan typically have 15-24 months before CHF onset. Once in Stage C, median survival is approximately 6-12 months, though some dogs stabilize for 2+ years with good medication compliance. Stage D survival is typically weeks to a few months.
Is canine mitral valve disease hereditary?
Yes. In Cavalier King Charles Spaniels, MMVD has a documented polygenic inheritance pattern. Breeding programs using echocardiographic screening of breeding stock (recommended by the AKC and breed clubs) aim to reduce prevalence. If you are acquiring a puppy from a predisposed breed, ask the breeder for cardiac screening results of the sire and dam.
Can I prevent mitral valve disease in my dog?
There is no proven method to prevent the onset of myxomatous degeneration. However, early detection through annual auscultation (and echocardiographic screening for high-risk breeds starting at age 2-3) allows timely intervention. Maintaining lean body condition reduces cardiac workload — obesity is a modifiable risk factor for faster progression.
Does my dog need to see a veterinary cardiologist?
For Stage A-B1, a general practitioner can monitor with annual exams. For Stage B2 and beyond, a cardiology referral is strongly recommended for echocardiographic staging, medication titration, and advanced monitoring. If a cardiologist is not accessible in your area, many offer telemedicine consults where your primary vet performs the echo and the cardiologist interprets remotely.
How is canine mitral valve disease different from human mitral valve disease?
Humans most commonly develop mitral valve prolapse (MVP) or rheumatic mitral stenosis. Dogs develop myxomatous degeneration that is histologically similar to human MVP but far more prevalent in small breeds and more rapidly progressive relative to lifespan. Human mitral valve repair/replacement surgery is routine; in dogs, it remains experimental and available at very few centers worldwide. Medical management is the primary approach in veterinary medicine.
Key References
- Merck Veterinary Manual: Myxomatous Atrioventricular Valvular Disease in Dogs
- Boswood, A. et al. (2016). "Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study." Journal of Veterinary Internal Medicine, 30(6), 1765-1779.
- Keene, B.W. et al. (2019). "ACVIM Consensus Guidelines for the Diagnosis and Treatment of Myxomatous Mitral Valve Disease in Dogs." Journal of Veterinary Internal Medicine, 33(3), 1127-1140.
Priya Sutaria
All our authors care for dogs every day — read more of their work on the authors page.
